10:42 AM EST, 01/22/2025 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said Wednesday that the first patient has been dosed in a phase 3 study of its investigational NTLA-2002 treatment of hereditary angioedema, a disorder that results in recurrent attacks of severe swelling.

The trial will evaluate the efficacy and safety of NTLA-2002 in 60 adults, with enrollment expected to be completed in H2.

Intellia said it expects to submit a biologics license application next year to support its plans for a US launch in 2027.

The company's shares were up 1.5% in recent trading.

Price: 10.09, Change: +0.15, Percent Change: +1.51